Rifai AR - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.

Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Lim YL, et al. Suharyono, et al. Among authors: rifai ar. Lancet. 1992 Sep 19;340(8821):689-94. doi: 10.1016/0140-6736(92)92231-4. Lancet. 1992. PMID: 1355798 Clinical Trial.

Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children.

Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai AR, et al. Simanjuntak CH, et al. Among authors: rifai ar. J Infect Dis. 1993 Nov;168(5):1169-76. doi: 10.1093/infdis/168.5.1169. J Infect Dis. 1993. PMID: 8228350 Clinical Trial.

Association Between the Effectiveness and Immunogenicity of Inactivated SARS-CoV2 Vaccine (CoronaVac) with the Presence of Hypertension among Health Care Workers.

Rifai A, Wahono CS, Pratama MZ, Handono K, Susianti H, Iskandar A, Diyah N, Santoningsih D, Samsu N, Gunawan A. Rifai A, et al. Clin Exp Hypertens. 2022 Apr 3;44(3):233-239. doi: 10.1080/10641963.2021.2022687. Epub 2022 Jan 7. Clin Exp Hypertens. 2022. PMID: 34994256 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters